Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Unknown 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 3Thoracic 1Head & Neck 1

Conditions

Brain Neoplasms 3Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × 5-fluoropentyl-2-methylmalonic acid × Clear all
NCT00696943 2013-02-15

18F ML-10 for Early Detection of Response of Brain Metastases to SRS

Aposense Ltd.

Phase 2 Terminated
1 enrolled
CNS

Brain Neoplasms

NCT00791063 2013-02-13

18F ML-10 for Early Detection of Response of Brain Metastases to WBRT

Aposense Ltd.

Phase 2 Completed
10 enrolled
CNS

Brain Neoplasms

NCT01260480 2010-12-17

An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation

Aposense Ltd.

Phase 2 Unknown
60 enrolled
Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

NCT00805636 2010-05-12

Evaluation of the Efficacy and Safety of [18F]-ML-10, as a PET Imaging Radiotracer, in Early Detection of Response of Brain Metastases of Solid Tumors to Radiation Therapy.

Aposense Ltd.

Phase 2 Unknown
30 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡